BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/18/2025 8:11:49 AM | Browse: 162 | Download: 486
 |
Received |
|
2024-08-07 02:11 |
|
Peer-Review Started |
|
2024-08-07 02:11 |
|
First Decision by Editorial Office Director |
|
2024-10-11 09:58 |
|
Return for Revision |
|
2024-10-11 09:58 |
|
Revised |
|
2024-10-23 03:46 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2024-11-05 02:40 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-11-05 07:34 |
|
Articles in Press |
|
2024-11-05 07:34 |
|
Edit the Manuscript by Language Editor |
|
2024-11-13 03:40 |
|
Typeset the Manuscript |
|
2024-11-19 03:47 |
|
Publish the Manuscript Online |
|
2025-01-18 08:11 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Immunology |
| Manuscript Type |
Editorial |
| Article Title |
Nucleotide-binding domain, leucine-rich repeat, and pyrin domain-containing protein 3 inflammasome: From action mechanism to therapeutic target in clinical trials
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Chun-Ye Zhang, Shuai Liu, Yu-Xiang Sui and Ming Yang |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Ming Yang, Assistant Professor, PhD, Department of Surgery, University of Connecticut, School of Medicine, 263 Farmington Avenue, Farmington, CT 06030, United States. minyang@uchc.edu |
| Key Words |
Nucleotide-binding domain, leucine-rich repeat, and pyrin domain-containing protein 3; Metabolic disease; Inflammation; Cancer; Immunotherapy; Clinical trial |
| Core Tip |
The nucleotide-binding domain, leucine-rich repeat, and pyrin domain-containing protein 3 (NLRP3) inflammasome plays a pivotal role in many diseases such as inflammatory diseases, metabolic disorders, and neurodegenerative diseases. The investigation of NLRP3 as a therapeutic target is involved in many preclinical studies and clinical trials. Among these studies, NLRP3 inhibitors and downstream interleukin-1 inhibitors attract wide-spectrum attention. In addition, NLRP3 activation also impacts cancer development and immunotherapy, serving as a potential therapeutic target for cancer treatment. |
| Publish Date |
2025-01-18 08:11 |
| Citation |
Zhang CY, Liu S, Sui YX, Yang M. Nucleotide-binding domain, leucine-rich repeat, and pyrin domain-containing protein 3 inflammasome: From action mechanism to therapeutic target in clinical trials. World J Gastrointest Oncol 2025; 17(2): 100094 |
| URL |
https://www.wjgnet.com/1948-5204/full/v17/i2/100094.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v17.i2.100094 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
